logo
Is this the beginning of the end for price-matching policies?

Is this the beginning of the end for price-matching policies?

Independent7 days ago
Target is ending its policy of matching competitor prices from retailers such as Amazon and Walmart, effective 28 July.
Introduced in 2013, the policy previously allowed price matching with Target.com, Amazon, and Walmart; under the new rules, only Target.com prices will be matched.
Retail analysts suggest this change reflects Target's ongoing financial challenges and efforts to improve profitability and margins.
The company recently reported a 2.8 per cent drop in first-quarter sales, falling short of Wall Street's expectations.
Target has encountered various financial headwinds, including economic uncertainty from a previous administration's tariff regime, rising inflation, and consumer boycotts.
Here's why Target is ending its long-running 'price matching' policy this month
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Gold hovers near 3-week low as trade war fears ebb, dollar firms
Gold hovers near 3-week low as trade war fears ebb, dollar firms

Reuters

time12 minutes ago

  • Reuters

Gold hovers near 3-week low as trade war fears ebb, dollar firms

July 29 (Reuters) - Gold prices were little changed on Tuesday, hovering near a three-week low, as easing fears of a global tariff war and a stronger dollar dampened bullion's safe-haven appeal. Spot gold held its ground at $3,318.79 per ounce, as of 0210 GMT. Bullion hit its lowest level since July 9 in the previous session. U.S. gold futures edged 0.2% higher to $3,317.50. "Gold trading at circa $3,300 or below is still getting the attention of buyers. While short-term market dynamics courtesy of trade deals and a stronger USD aren't helping gold, looking further ahead there is still upside potential," KCM Trade Chief Market Analyst Tim Waterer said. Top U.S. and Chinese economic officials met in Stockholm on Monday for more than five hours of talks aimed at resolving longstanding economic disputes at the centre of a trade war between the world's top two economies, seeking to extend a truce by three months. The U.S. struck a framework trade agreement with the European Union on Sunday, imposing a 15% import tariff on most EU goods - half the threatened rate - and averting a bigger trade war between the two allies that account for almost a third of global trade. The U.S. dollar index (.DXY), opens new tab held near a more than one-week high, making gold costlier for buyers holding other currencies. Investors are awaiting a set of U.S. macroeconomic data this week, including inflation figures and the employment report, alongside the Federal Reserve's two-day policy meeting beginning later in the day, with expectations largely pointing to rates being held steady. If weaker U.S. macro data emerges or Trump's criticisms of the Fed inspire the central bank to adopt a more dovish tone this week, that could be positive for gold, Waterer said. Spot silver was down 0.2% at $38.10 per ounce, while platinum gained 0.5% to $1,396.35 and palladium fell 1.2% to $1,231.55.

South Korea's Celltrion says tapped to buy US pharma factory to offset tariff risk
South Korea's Celltrion says tapped to buy US pharma factory to offset tariff risk

Reuters

time42 minutes ago

  • Reuters

South Korea's Celltrion says tapped to buy US pharma factory to offset tariff risk

SEOUL, July 29 (Reuters) - South Korean pharmaceutical firm Celltrion ( opens new tab said on Tuesday that in an attempt to offset the risk of U.S. tariffs it had become the preferred bidder to acquire a U.S. manufacturing factory from an unnamed global pharmaceutical company. Celltrion's Founder and Chief Executive Seo Jung-jin told a briefing it planned to invest 700 billion won ($503.78 million) in the acquisition and operation of the factory, without giving a breakdown of the figure. The company could make an additional investment ranging from 300 billion won to 700 billion won depending on U.S. tariff policy. The U.S. has been conducting a national security investigation into the pharmaceutical sector and President Donald Trump said earlier this month that pharmaceutical tariffs could be as high as 200%. He expected the tariffs to offer "opportunities" by increasing drug prices and reducing competition, thus improving profitability. Celltrion said it would not disclose further details, including the name of the seller and its location, until the signing of the final agreement, which is expected in early October.

Von der Leyen ducks Trump's trade blitz – but deal exposes EU's faultlines
Von der Leyen ducks Trump's trade blitz – but deal exposes EU's faultlines

The Guardian

timean hour ago

  • The Guardian

Von der Leyen ducks Trump's trade blitz – but deal exposes EU's faultlines

There is no doubt that Ursula von der Leyen was under intense pressure on Sunday when she sat next to Donald Trump in the ballroom at his Turnberry golf course before what EU officials knew would be a gruelling round of trade talks. As the European Commission president emerged less than an hour later to announce that the worst of Trump's tariff threats had been avoided, the recriminations from inside the EU began almost immediately. Under the deal agreed in Scotland, an economically devastating trade war has been prevented. Still, European leaders are eyeing up the cost to the bloc from being locked in to tariffs of 15% on most EU exports to the US, when they had previously averaged 4.8%. French and German leaders, following in the footsteps of Hungary's prime minister, Viktor Orbán, focused on this outcome, rather than the potential damage that could have been inflicted by a US president with an intense dislike for the EU. The French prime minister, François Bayrou, was among leaders who thought Trump's threatened 30% rate could at least be lowered to match the 10% tariff deal secured by the UK. He said the EU had capitulated and described Sunday as a 'dark day'. The irony of one leader beset by factional warring berating another for failing to present a united front to the US was lost on Bayrou. There were many in Brussels who thought he might have taken a more emollient tone given that parliamentary infighting has prevented him from passing a long-delayed budget bill. And especially when Paris is often the cause of friction inside the EU's Brussels headquarters. On this occasion, Bayrou objected to the EU threat of tariffs on US bourbon, fearing that French wine and brandy producers might be caught in the crossfire. Some insiders asked how the commission president could go nose-to-nose with Trump when the EU was, and remains, divided, with member states seeking carve-outs for their own vulnerable industries. Von der Leyen can also say that most of the trade concessions, including a commitment to buy a large quantity of gas from US producers, matter little when the purchases were likely to be made anyway. She is also hopeful that the deal can circumvent Trump's obsession with the US pharmaceutical industry. The sector has been left out of all trade deals so far, which means no one yet knows what US tariffs on pharmaceutical imports will be. Ireland is especially fearful after accumulating much of the US offshore pharma industry in County Cork. Brussels is hopeful that 15% will also be the tariff on EU-based pharma exports to the US. David Henig, the director of the UK trade policy project at the European Centre for International Political Economy, said the result of Trump's actions would probably hit trade and economic growth on both sides of the Atlantic, but only marginally. 'Nobody wins, there are unlikely to be big trade shifts, but the world keeps turning,' he said. Sign up to Business Today Get set for the working day – we'll point you to all the business news and analysis you need every morning after newsletter promotion HSBC economists said the 15% tariff would be offset by a reduction in uncertainty hitting businesses that had been weighing heavily on trade, leaving the EU to face 'a fairly marginal impact'. There is also much left to negotiate on a deal, which at present is more like an impressionist painting than a clearcut photograph. As the summer turns to autumn, von der Leyen must hope the German chancellor, Friedrich Merz, and Italy's prime minister, Giorgia Meloni, refuse to join Bayrou in criticising the deal for fear of handing Trump even more negotiating power in the detailed phase. The obvious weakness in the EU's negotiating position may have the opposite effect by encouraging more leaders to consider changes put forward by the former Italian prime minister and European Central Bank chief, Mario Draghi, who estimated that internal trade barriers within the bloc amount to almost 50% on goods and 110% on services. Draghi's call for a collective endeavour on both investment and regulation is the best blueprint for leaders who know that pursuing sectional national interests is economically and socially illiterate. The problem is that von der Leyen's trade fudge – minimising the impact of Trump's threats – will allow the EU to continue muddling through, and leave Draghi's report to gather more dust.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store